Huang: Aβ as a Two-Faced Molecule

Benjamin Aaron Gustafsson AdultCognitiveDisease.com

An Evaluation of Zhen Huang's Competitive Synaptic

Plasticity Hypothesis and the Monomer Depletion

Model in Alzheimer's Disease Pathogenesis

Abstract

For over three decades, the Amyloid Cascade Hypothesis has dominated Alzheimer's disease (AD) research, positing that insoluble amyloid-beta (Aβ) accumulation drives neurodegeneration. However, repeated clinical failures of anti-amyloid monotherapies to arrest cognitive decline have prompted re-evaluation of Aβ's physiological roles. This analysis examines the theoretical framework proposed by Zhen Huang, whose 2024 publications articulate a hypothesis: the Competitive Synaptic Plasticity model. The framework proposes that Aβ exhibits concentration-dependent effects—at low concentrations, monomeric Aβ provides a neurotrophic signal suppressing microglial inflammation via APP and Ric8a signaling; at high concentrations, oligomeric Aβ triggers microglial activation and synaptic pruning. Consequently, Alzheimer's disease is characterized by "monomer depletion"—a state wherein Aβ aggregation depletes the soluble monomer pool, removing the physiological brake on microglia and inciting chronic neuroinflammation. This analysis synthesizes molecular, genetic, and clinical evidence to assess how well Huang's framework accounts for AD pathogenesis and identifies critical gaps and untested predictions.

Introduction: Clinical Failures and the Need for Reconceptualization

Alzheimer's disease represents a major neurobiological and socioeconomic challenge, characterized by progressive synaptic loss, neuronal death, and cognitive decline. Histologically, the disease is defined by extracellular amyloid plaques and intracellular tau tangles. The Amyloid Cascade Hypothesis, formulated in the 1990s following discovery of APP and presenilin mutations, posited that Aβ overproduction or impaired clearance initiates a linear pathological cascade. The field currently faces significant challenges reconciling theory with clinical outcomes. Amyloid plaque burden does not correlate consistently with cognitive decline severity; individuals with extensive amyloid pathology can remain cognitively intact; and amyloid-clearing monoclonal antibodies show modest clinical benefit. These observations suggest that fibrillar Aβ accumulation alone is insufficient to explain AD pathogenesis. Zhen Huang's competitive synaptic plasticity framework proposes an alternative: Alzheimer's disease reflects a failure of activity-dependent synaptic competition, mediated by concentration-dependent Aβ signaling.⁸ The hypothesis advances that Aβ is a conserved peptide regulating synaptic competition, with monomeric Aβ providing protective signals and oligomeric Aβ driving destructive pruning. The critical addition is "monomer depletion"—the hypothesis that Aβ aggregation strips the brain of soluble monomers, removing an essential anti-inflammatory signal.

Part 1: The Biphasic Model of Aβ Function

Structural and Functional Homology with Antimicrobial Peptides

The hypothesis draws an analogy between Aβ and bacterial antimicrobial peptides (AMPs), notably nisin. In bacteria like Lactococcus lactis, nisin functions as both a protective autocrine signal at low concentrations and a competitive toxin at high concentrations. At low cell densities, nisin monomers activate surface receptors conferring self-protection; at high densities, nisin oligomerizes to form membrane pores in competitor cells. The hypothesis proposes that mammalian nervous systems co-opted this mechanism for synaptic competition. Evidence supports biphasic Aβ effects: at picomolar to low nanomolar concentrations, Aβ monomers enhance synaptic vesicle recycling, increase neurotransmitter release probability, and lower long-term potentiation (LTP) induction thresholds.²¹ Conversely, at higher concentrations, oligomeric Aβ inhibits exocytosis, depletes vesicle pools, and promotes long-term depression (LTD).²¹ What remains to be established: Whether the nisin analogy explains the concentration thresholds governing Aβ monomer-to-oligomer transitions in vivo, or whether this transition is driven primarily by local activity-dependent factors, aggregation kinetics, or clearance capacity.⁸ Direct measurement of Aβ monomer concentrations in different brain regions and states is limited.

Immune Modulation by Concentration-Dependent Aβ

Monomeric Aβ activates phosphatidylinositol 3-kinase (PI3K) and Akt pathways in microglia, triggering anti-inflammatory responses. Oligomeric and fibrillar Aβ bind pattern recognition receptors (Toll-like receptors 2 and 4, TREM2), provoking pro-inflammatory cytokine production and synaptic engulfment. This biphasic immune effect has been documented in multiple cell culture and animal models. Limitations: The in vivo concentration thresholds distinguishing monomeric from oligomeric signaling in human brain remain uncertain. The relationship between local oligomer formation and systemic immune responses is incompletely characterized.

Part 2: Synaptic Execution via Fitness Checkpoint Proteins

The hypothesis integrates Aβ signaling with cellular fitness competition mechanisms, centering on the Flower (Fwe) protein. Flower proteins were originally identified in Drosophila as markers distinguishing "winner" and "loser" cells in competitive interactions. Fitter cells express FlowerUbi isoforms, while stressed cells express FlowerLose isoforms. The hypothesis proposes that when Aβ oligomers damage a synapse, that synapse upregulates FlowerLose isoforms, marking it for microglial elimination. Loss-of-function studies in APP and PirB knockout mice show impaired synaptic refinement, consistent with a role for Aβ-mediated pruning signals. Recent literature indicates this system functions in mammalian developing brain, though the extent of continued operation in the adult human brain requires further clarification. The specific mechanisms linking Aβ-induced hyperactivity to FlowerLose expression remain incompletely defined. What remains uncertain: Whether FlowerLose-expressing synapses are preferentially pruned in aging human brain, or whether this system becomes less engaged with age. The quantitative relationship between oligomeric Aβ exposure and FlowerLose induction is not established.

Microglial Recruitment and Synaptic Phagocytosis

Oligomeric Aβ induces phosphatidylserine externalization on synaptic membranes—an "eat-me" signal. Microglia expressing TREM2 and complement receptor 3 recognize opsonized synapses and execute phagocytosis. This coordination between neuronal signals and microglial response is well-documented in neurodevelopmental pruning. Outstanding questions: The extent to which this developmental mechanism remains active in aging brain and whether its dysregulation specifically drives AD-like pathology remains incompletely tested in human tissues.

Part 3: The APP-Ric8a Signaling Axis

A 2024 eLife publication identified that monomeric Aβ binds microglial APP, initiating signaling through heterotrimeric G-proteins requiring Ric8a (a GEF stabilizing G-alpha subunits). Conditional knockout mice lacking Ric8a or App in microglia showed constitutive microglial hyperactivity and exaggerated inflammatory responses to lipopolysaccharide and viral mimics. In vitro, monomeric Aβ40 suppressed cytokine induction in wild-type microglia but failed in Ric8a knockouts, supporting the necessity of this pathway for Aβ-mediated immune suppression.³¹ Critical limitations: These data derive from murine models and in vitro systems. Direct evidence that this pathway functions in human microglial cells from healthy and AD-affected brain is limited. The developmental complexity surrounding Emx1-Cre driver expression in certain progenitor pools adds interpretive caution to some knockout results.

MMP9 and Extracellular Matrix Degradation

Microglial loss of the Aβ-mediated brake results in excessive matrix metalloproteinase 9 (MMP9) release. In developing brain, this causes severe neuronal migration defects (cobblestone lissencephaly-like phenotype).¹⁰ In aging brain, unchecked MMP9 could degrade perineuronal nets—protective extracellular matrix structures stabilizing established connections—potentially exposing synapses to aberrant pruning. Unresolved: Whether age-related increases in microglial MMP9 specifically correlate with perineuronal net degradation in human AD brain, and whether this accounts for a substantive fraction of synaptic loss.

Part 4: The Monomer Depletion Hypothesis

The hypothesis proposes that AD represents not merely a "proteinopathy" (toxic aggregation) but equally a "proteinopenia" (functional loss of soluble signaling molecules).³⁸ As Aβ peptides aggregate into oligomers and plaques, they draw from the soluble monomer pool. Familial AD mutations increase the Aβ42/Aβ40 ratio, driving more rapid aggregation. Because Aβ42 is highly hydrophobic and self-aggregating, it forcefully depletes monomeric pools. In familial cases, autosomal dominant mutations alter cleavage kinetics, increasing amyloidogenic Aβ42 production. In sporadic AD, the mechanism driving monomer depletion is less clearly articulated—the hypothesis suggests age-related microglial dysregulation alters pruning thresholds, but the quantitative contribution of this mechanism compared to impaired clearance or altered secretion is uncertain.

Bridging Amyloid and Tau Pathology

The hypothesis proposes that monomer depletion removes the microglial brake, inciting a cytokine storm that drives tauopathy as a secondary, kinase-driven consequence. However, the specific kinase pathways linking IL-1β, IL-6, and TNFα to tau phosphorylation and propagation remain incompletely specified. Significant gap: Direct evidence that selective monomer depletion (independent of oligomer toxicity) drives tau pathology is lacking. The relative contribution of monomer loss versus oligomer-mediated effects has not been rigorously separated.

Clinical and Translational Implications

The hypothesis suggests new therapeutic opportunities: preserving monomeric Aβ while reducing oligomer and plaque burden, rather than clearing all Aβ. This differs markedly from anti-amyloid monoclonal antibody strategies, which reduce both monomers and aggregated forms. Some clinical biomarker data show that low cerebrospinal fluid soluble Aβ42 correlates with cognitive decline and amyloid pathology, consistent with a monomer depletion signature. However, direct evidence that increasing soluble monomers—or preventing their depletion—alters disease progression in humans remains absent. Critical limitation: No human trials have tested whether selective monomer preservation strategies slow cognitive decline. The therapeutic window for such approaches—if it exists—is unknown.⁴

What This Analysis Cannot Determine

1. Concentration thresholds and kinetics: The precise in vivo concentrations of Aβ monomers, oligomers, and fibrils in human brain, and the kinetics of transitions between these states, remain experimentally inaccessible in living human subjects. CSF measurements provide limited spatial and temporal resolution.
2. Causality of monomer depletion: Whether the observed low CSF soluble Aβ in AD-affected individuals is causally driving disease progression or is a secondary consequence of aggregation and clearance changes is not definitively established.
3. Specification of tau pathology mechanisms: The specific kinase pathways and molecular events linking microglial disinhibition to hyperphosphorylation and propagation of tau require more detailed mechanistic characterization. The claim that tau pathology is "downstream" of monomer depletion is plausible but remains largely inferential.
4. Age-related microglial dysregulation: The hypothesis attributes sporadic AD in large part to age-related changes in microglial responsiveness to monomeric Aβ, but the molecular basis for this dysregulation (changes in APP expression, Ric8a function, receptor coupling, intracellular signaling) is not fully characterized.
5. Quantitative contributions: For cases with mixed pathology (amyloid, tau, neurodegeneration, vascular changes), the framework does not specify quantitatively how much variance in cognitive decline is attributable to monomer depletion versus other mechanisms.
6. Human validation of Flower protein involvement: While Flower proteins operate in developing mammalian brain, their continued function in adult human brain, and their specific role in AD-related synaptic loss, requires direct cellular and tissue-level evidence.
7. Integration with genetic heterogeneity: Late-onset AD is genetically heterogeneous (APOE, TREM2, CD33, CR1, ABCA1, and many others). How the monomer depletion model accounts for risk alleles affecting diverse pathways—some immune-focused, others lipid-related—is incompletely articulated.
8. Clinical efficacy of preservation strategies: No human data demonstrate that preventing monomer depletion, or restoring monomeric Aβ, slows or arrests cognitive decline. The therapeutic hypothesis is mechanistically coherent but clinically unvalidated.⁴

The Validity Ledger

The argument above is only as strong as its weakest load-bearing joint, and the reader is owed an explicit accounting of where it stands on the ground and where it stands on inference.

Conclusion

Huang's competitive synaptic plasticity hypothesis and monomer depletion model provide a mechanistically coherent and integrative framework for understanding Alzheimer's disease. The hypothesis unifies amyloid, tau, and neuroinflammation into a single narrative centered on activity-dependent synaptic competition, with biphasic Aβ signaling as the organizing principle.⁸ The framework is well-supported by molecular and genetic evidence from animal models demonstrating biphasic Aβ effects, the APP-Ric8a microglial signaling axis, and the role of fitness checkpoint proteins in synaptic competition. The integration of these mechanisms is intellectually coherent and addresses historical contradictions in the field. However, significant gaps remain: direct demonstration that monomer depletion (independently of oligomer toxicity) drives pathology; clarification of the molecular mechanisms linking microglial disinhibition to tauopathy; validation of Flower protein involvement in adult AD brain; and, most critically, clinical evidence that preventing monomer depletion or restoring monomeric Aβ improves outcomes in human subjects. The hypothesis advances the field by proposing testable predictions: (1) preservation of monomeric Aβ while reducing aggregated forms should slow cognitive decline more effectively than broad Aβ clearance; (2) biomarkers of monomer depletion should predict disease progression more accurately than amyloid or tau burden alone; (3) Flower protein expression patterns in AD-affected brain tissue should distinguish vulnerable from resilient neurons. Until these predictions are tested in human cohorts and clinical trials, the monomer depletion model remains a valuable conceptual framework rather than validated etiology.

Works Cited

1. Ferrer I. Alzheimer's disease is an inherent, natural part of human brain aging: an integrated perspective. Free Neuropathol 2022;3:17.

   Find this paper

2. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron 2014;82(4):756-71. DOI 10.1016/j.neuron.2014.05.004.

3. Yan R. Faculty Opinions recommendation of Synaptogenic effect of APP-Swedish mutation in familial Alzheimer's disease. Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 2022. DOI 10.3410/f.742372058.793596137.

4. Sturchio A, Dwivedi AK, Malm T, Wood MJA, Cilia R, Sharma JS, et al.. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations. J Alzheimers Dis 2022;90(1):333-348. DOI 10.3233/JAD-220808.

5. Knopman DS, Hershey L. Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care. Neurology 2023;101(14):610-620. DOI 10.1212/WNL.0000000000207438.

6. Alzheimer's researchers awarded $4M in Oskar Fischer Prizes from UTSA, accessed March 23, 2026, https://news.utsa.edu/2022/06/alzheimers-researchers-awarded-4m-in-oskar-fischer-prizes-from-utsa/

7. OFP_2020_paper_28.pdf

8. Huang Z. Evidence that Alzheimer's Disease Is a Disease of Competitive Synaptic Plasticity Gone Awry. J Alzheimers Dis 2024;99(2):447-470. DOI 10.3233/JAD-240042.

9. Tissir F. eLife Assessment: A novel monomeric amyloid β-activated signaling pathway regulates brain development via inhibition of microglia. 2024. DOI 10.7554/elife.100446.3.sa0.

10. Huang Z. A Function of Amyloid-β in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology. J Alzheimers Dis 2023;92(1):29-57. DOI 10.3233/JAD-221042.

11. Bermejo-Pareja F, Del Ser T. Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History. J Clin Med 2024;13(2). DOI 10.3390/jcm13020536.

12. Princiotta Cariddi L, Mauri M, Cosentino M, Versino M, Marino F. Alzheimer's Disease: From Immune Homeostasis to Neuroinflammatory Condition. Int J Mol Sci 2022;23(21). DOI 10.3390/ijms232113008.

13. MR.K.SATHISH M, K.MADHURI K, R.SATHVIKA R, P.RAJU P, S.SAGAR S. ARTIFICIAL INTELLIGENCE IN SCIENCE AND SOCIETY: THE VISION OF USERN. INTERNATIONAL JOURNAL OF ENGINEERING DEVELOPMENT AND RESEARCH 2026;14(2). DOI 10.56975/ijedr.v14i2.307275.

14. Miller SJ, Logan R, Zhang C, Hafler BP. The amyloid-beta wave hypothesis of Alzheimer's disease. Front Cell Infect Microbiol 2025;15:1723095. DOI 10.3389/fcimb.2025.1723095.

15. Beyond Association: A Quantitative Analysis of the Infectious Burden in Alzheimer's Disease - medRxiv, accessed March 23, 2026, DOI 10.64898/2025.12.24.25342962">https://www.medrxiv.org/content/10.64898/2025.12.24.25342962

16. Wani NA, Gazit E, Ramamoorthy A. Interplay between Antimicrobial Peptides and Amyloid Proteins in Host Defense and Disease Modulation. Langmuir 2024;40(48):25355-25366. DOI 10.1021/acs.langmuir.4c03123.

17. Huang Z. Evidence that Alzheimer's Disease Is a Disease of Competitive Synaptic Plasticity Gone Awry. J Alzheimers Dis 2024;99(2):447-470. DOI 10.3233/JAD-240042.

18. Gulisano W, Melone M, Ripoli C, Tropea MR, Li Puma DD, Giunta S, et al.. Neuromodulatory Action of Picomolar Extracellular Aβ42 Oligomers on Presynaptic and Postsynaptic Mechanisms Underlying Synaptic Function and Memory. The Journal of Neuroscience 2019;39(30):5986-6000. DOI 10.1523/jneurosci.0163-19.2019.

19. Ric-8A and Ric-8B interact with different subsets of G proteins in the... - ResearchGate, accessed March 23, 2026, https://www.resea rchgate.net/figure/Ric-8A-and-Ric-8B-interact-with-different-subsets-of-G-proteins-in-the-yeast-two-hybrid_fig2_10967778

20. Characterising the Modulatory Role of Ikebana in Flower-Dependent Cell Competition, accessed March 23, 2026, https://www.biorxiv.org/content/

21. Clavería C, Torres M. Cell Competition: Mechanisms and Physiological Roles. Annual Review of Cell and Developmental Biology 2016;32(1):411-439. DOI 10.1146/annurev-cellbio-111315-125142.

22. Vesicles & Endoplasmic Reticulum - Society for Developmental Biology, accessed March 23, 2026, https://www.sdbonline.org/sites/fly/aignfam/vesicles.htm

23. Gene - fwe flower [Drosophila melanogaster (fruit fly)] - NCBI - NIH, accessed March 23, 2026, https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd;=DetailsSearch&Term;=39720

24. Costa-Rodrigues C, Couceiro J, Moreno E. Cell competition from development to neurodegeneration. Dis Model Mech 2021;14(7). DOI 10.1242/dmm.048926.

25. Gutiérrez-García A, Marques-Reis M, Moreno E. Imaging Cell Competition in Ex-Vivo Drosophila Adult Brains. Methods Protoc 2025;9(1). DOI 10.3390/mps9010001.

26. Yeates C, Deshpande P, Kango-Singh M, Singh A. Signaling interactions among neurons impact cell fitness and death in Alzheimer's disease. Neural Regen Res 2023;18(4):784-789. DOI 10.4103/1673-5374.354516.

27. Fantová T, Warmuzová M, Charvátová S, Stošková K, Jelínek T, Šimíček M, et al.. Winners take it all: turning cell competition into a therapeutic ally. Cell Commun Signal 2026;24(1):87. DOI 10.1186/s12964-025-02611-3.

28. Huang Z. Evidence that Alzheimer's Disease Is a Disease of Competitive Synaptic Plasticity Gone Awry. J Alzheimers Dis 2024;99(2):447-470. DOI 10.3233/JAD-240042.

29. Kwon HJ, Santhosh D, Huang Z. A novel monomeric amyloid β-activated signaling pathway regulates brain development via inhibition of microglia. Elife 2024;13. DOI 10.7554/eLife.100446.

30. Kwon HJ, Santhosh D, Huang Z. A novel monomeric amyloid β-activated signaling pathway regulates brain development via inhibition of microglia. Elife 2024;13. DOI 10.7554/eLife.100446.

31. Structure of the Ric8A armadillo core - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/figure/Structure-of-the-Ric8A-armadillo-core_fig3_334427458

32. Kwon HJ, Santhosh D, Huang Z. A novel monomeric amyloid β-activated signaling pathway regulates brain development via inhibition of microglia. Elife 2024;13. DOI 10.7554/eLife.100446.

33. Galvani G, Mottolese N, Gennaccaro L, Loi M, Medici G, Tassinari M, et al.. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder. J Neuroinflammation 2021;18(1):155. DOI 10.1186/s12974-021-02204-0.

34. Kask K, Ruisu K, Tikker L, Karis K, Saare M, Meier R, et al.. Deletion of RIC8A in neural precursor cells leads to altered neurogenesis and neonatal lethality of mouse. Dev Neurobiol 2015;75(9):984-1002. DOI 10.1002/dneu.22264.

35. Temporal differences in cerebral cortex pathology in dystroglycan-null... - ResearchGate, accessed March 23, 2026, https://www.researchgate.net/figure/Temporal-differences-in-cerebral-cortex-pathology-in-dystroglycan-null-mice-A-B_fig4_47566605

36. Murase S, Winkowski D, Liu J, Kanold PO, Quinlan EM. Homeostatic regulation of perisynaptic matrix metalloproteinase 9 (MMP9) activity in the amblyopic visual cortex. Elife 2019;8. DOI 10.7554/eLife.52503.

37. Pitton Rissardo J, Fornari Caprara AL. A Biophysical Framework for Neurodegeneration: Prioritizing Protein Homeostasis Over Aggregate Toxicity. 2025. DOI 10.20944/preprints202512.2722.v1.

38. Kwon HJ, Santhosh D, Huang Z. A novel monomeric amyloid β-activated signaling pathway regulates brain development via inhibition of microglia. Elife 2024;13. DOI 10.7554/eLife.100446.

39. Abbate C. The Adult Neurogenesis Theory of Alzheimer's Disease. J Alzheimers Dis 2023;93(4):1237-1276. DOI 10.3233/JAD-221279.

40. Sturchio A, Dwivedi AK, Malm T, Wood MJA, Cilia R, Sharma JS, et al.. High Soluble Amyloid-β42 Predicts Normal Cognition in Amyloid-Positive Individuals with Alzheimer's Disease-Causing Mutations. J Alzheimers Dis 2022;90(1):333-348. DOI 10.3233/JAD-220808.

41. Sha S, Ren L, Xing X, Guo W, Wang Y, Li Y, et al.. Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer's disease. Neural Regen Res 2026;21(2):577-587. DOI 10.4103/NRR.NRR-D-24-00846.